ECSP16079730A - 2-AMINO-6-METIL-4,4a,5,6-TETRAHIDROPIRANO[3,4-d][1,3]TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILAMIDAS - Google Patents

2-AMINO-6-METIL-4,4a,5,6-TETRAHIDROPIRANO[3,4-d][1,3]TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILAMIDAS

Info

Publication number
ECSP16079730A
ECSP16079730A ECIEPI201679730A ECPI201679730A ECSP16079730A EC SP16079730 A ECSP16079730 A EC SP16079730A EC IEPI201679730 A ECIEPI201679730 A EC IEPI201679730A EC PI201679730 A ECPI201679730 A EC PI201679730A EC SP16079730 A ECSP16079730 A EC SP16079730A
Authority
EC
Ecuador
Prior art keywords
ilamides
thiazin
tetrahydropyran
thiazol
amino
Prior art date
Application number
ECIEPI201679730A
Other languages
English (en)
Inventor
Michael Aaron Brodney
Elizabeth Mary Beck
Brian Thomas O'neill
Christopher Ryan Butler
Erik Alphie Lachapelle
Bruce Nelsen Rogers
Lei Zhang
Gabriela Barreiro
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of ECSP16079730A publication Critical patent/ECSP16079730A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a compuestos, tautómeros y sales farmacéuticamente aceptables de los compuestos que se revelan, en donde los compuestos tienen la estructura de la fórmula I (ver anexo) y la variable R1 es como se define en la memoria descriptiva. También se revelan composiciones farmacéuticas, métodos de tratamiento, métodos de síntesis e intermediarios.
ECIEPI201679730A 2014-04-10 2016-10-07 2-AMINO-6-METIL-4,4a,5,6-TETRAHIDROPIRANO[3,4-d][1,3]TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILAMIDAS ECSP16079730A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461977774P 2014-04-10 2014-04-10
US201562119862P 2015-02-24 2015-02-24

Publications (1)

Publication Number Publication Date
ECSP16079730A true ECSP16079730A (es) 2019-07-31

Family

ID=53005609

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201679730A ECSP16079730A (es) 2014-04-10 2016-10-07 2-AMINO-6-METIL-4,4a,5,6-TETRAHIDROPIRANO[3,4-d][1,3]TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILAMIDAS

Country Status (26)

Country Link
US (5) US9315520B2 (es)
EP (1) EP3129388A1 (es)
JP (1) JP6111002B1 (es)
KR (2) KR20180078347A (es)
CN (1) CN106459088A (es)
AP (1) AP2016009493A0 (es)
AU (1) AU2015245260A1 (es)
CA (1) CA2944971C (es)
CL (1) CL2016002510A1 (es)
CR (1) CR20160455A (es)
CU (1) CU20160151A7 (es)
DO (1) DOP2016000276A (es)
EA (1) EA030085B1 (es)
EC (1) ECSP16079730A (es)
IL (1) IL248277A0 (es)
MA (1) MA39866A (es)
MD (1) MD20160105A2 (es)
MX (1) MX2016013329A (es)
PE (1) PE20170327A1 (es)
PH (1) PH12016501977A1 (es)
SG (1) SG11201607896YA (es)
SV (1) SV2016005294A (es)
TW (1) TWI551605B (es)
UY (1) UY36073A (es)
WO (1) WO2015155626A1 (es)
ZA (1) ZA201606517B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6043355B2 (ja) 2011-08-31 2016-12-14 ファイザー・インク ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物
US9403846B2 (en) 2012-12-19 2016-08-02 Pfizer Inc. Carbocyclic- and heterocyclic-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
CN106459088A (zh) * 2014-04-10 2017-02-22 辉瑞公司 2‑氨基‑6‑甲基‑4，4a，5，6‑四氢吡喃并[3，4‑d][1，3]噻嗪‑8a(8H)‑基‑1，3‑噻唑‑4‑基酰胺
JP2018534251A (ja) 2015-09-24 2018-11-22 ファイザー・インク Ｂａｃｅ阻害剤として有用なｎ−［２−（３−アミノ−２，５−ジメチル−１，１−ジオキシド−５，６−ジヒドロ−２ｈ−１，２，４−チアジアジン−５−イル）−１，３−チアゾール−４−イル］アミド
JP2018531923A (ja) 2015-09-24 2018-11-01 ファイザー・インク Ｎ−［２−（２−アミノ−６，６−二置換−４，４ａ，５，６−テトラヒドロピラノ［３，４−ｄ］［１，３］チアジン−８ａ（８Ｈ）−イル）−１，３−チアゾール−４−イル］アミド
WO2017051303A1 (en) 2015-09-24 2017-03-30 Pfizer Inc. Tetrahydropyrano[3,4-d][1,3]oxazin derivatives and their use as bace inhibitors
US10227810B2 (en) * 2016-08-03 2019-03-12 Ford Global Technologies, Llc Priority driven power side door open/close operations
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
US20200010057A1 (en) 2018-07-05 2020-01-09 Mando Corporation Drum brake
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
WO2020160156A2 (en) 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
TW202430514A (zh) 2022-09-30 2024-08-01 瑞士商先正達農作物保護股份公司 殺微生物之吡唑衍生物
TW202430031A (zh) 2022-09-30 2024-08-01 瑞士商先正達農作物保護股份公司 殺微生物之吡唑衍生物
WO2025114167A1 (en) 2023-11-28 2025-06-05 Syngenta Crop Protection Ag Microbiocidal pyrazole derivatives
WO2025191053A1 (en) 2024-03-14 2025-09-18 Syngenta Crop Protection Ag Microbiocidal pyrazole derivatives
WO2025210095A1 (en) 2024-04-03 2025-10-09 Syngenta Crop Protection Ag Microbiocidal tetrahydroisoquinoline compounds
WO2025210096A1 (en) 2024-04-03 2025-10-09 Syngenta Crop Protection Ag Fungicidal compositions

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0127584A1 (de) 1983-05-31 1984-12-05 Cantec, Inc. Förderschneckentransport zum Transportieren von sich folgenden Werkstücken zu einer Bearbeitungsmaschine mit auf einer Bahn umlaufenden Werkzeugen
ATE239797T1 (de) 1993-01-25 2003-05-15 Takeda Chemical Industries Ltd Antikörper gegen beta-amyloid oder derivative davon und seine verwendung
US8173127B2 (en) 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
NZ337765A (en) 1997-04-09 2001-09-28 Mindset Biopharmaceuticals Usa Recombinant antibodies having specificity for beta-amyloid N-terminus and C-terminus and use in treating Alzheimer's Disease
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
DE1257584T1 (de) 2000-02-24 2003-05-28 Lilly Co Eli Humanisierte antikörper, die amyloid beta peptid demarkieren
DE10045112A1 (de) 2000-09-11 2002-03-21 Merck Patent Gmbh Verwendung von Indolderivaten zur Behandlung von Erkrankungen des zentralen Nervensystems
CA2427661C (en) 2000-11-03 2013-05-28 Proteotech, Inc. Methods of isolating amyloid-inhibiting compounds and use of compounds isolated from uncaria tomentosa and related plants
CA2439152C (en) 2001-02-28 2008-06-17 Merck & Co., Inc. Acylated piperidine derivatives as melanocortin-4 receptor agonists
CA2451998A1 (en) 2001-08-17 2003-02-27 Eli Lilly And Company Anti-a.beta. antibodies
US20030195205A1 (en) 2001-11-02 2003-10-16 Pfizer Inc. PDE9 inhibitors for treating cardiovascular disorders
CN1642599A (zh) 2002-02-27 2005-07-20 辉瑞产品公司 Acc抑制剂
US20030236287A1 (en) 2002-05-03 2003-12-25 Piotrowski David W. Positive allosteric modulators of the nicotinic acetylcholine receptor
DE10238724A1 (de) 2002-08-23 2004-03-04 Bayer Ag Alkyl-substituierte Pyrazolpyrimidine
DE10238723A1 (de) 2002-08-23 2004-03-11 Bayer Ag Phenyl-substituierte Pyrazolyprimidine
US20040146512A1 (en) 2002-10-09 2004-07-29 Arnon Rosenthal Methods of treating Alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof
US20040220186A1 (en) 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
BRPI0410630A (pt) 2003-06-19 2006-06-13 Pfizer Prod Inc antagonista de nk1
EP1666061A1 (en) 2003-09-09 2006-06-07 Takeda Pharmaceutical Company Limited Use of antibody
GB0327319D0 (en) 2003-11-24 2003-12-24 Pfizer Ltd Novel pharmaceuticals
EP1720847A1 (en) 2004-02-02 2006-11-15 Pfizer Products Incorporated Histamine-3 receptor modulators
US7456164B2 (en) 2004-05-07 2008-11-25 Pfizer, Inc 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
PL1753748T3 (pl) 2004-05-12 2010-01-29 Pfizer Prod Inc Pochodne proliny i ich zastosowanie jako inhibitorów peptydazy dipeptylowej IV
EP1595881A1 (en) 2004-05-12 2005-11-16 Pfizer Limited Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands
AP2006003768A0 (en) 2004-05-25 2006-10-31 Pfizer Prod Inc TetraazabenzoÄeÜazulene derivatives and analogs tehereof
US20050267009A1 (en) 2004-05-28 2005-12-01 Deagle William R Method of Treatment of Acute and Persistent Pain
MX2007000998A (es) 2004-07-30 2007-07-11 Rinat Neuroscience Corp Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos.
US20090074775A1 (en) 2004-12-22 2009-03-19 David Michael Holtzman Use Of Anti-AB Antibody To Treat Traumatic Brain Injury
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
UY29504A1 (es) 2005-04-29 2006-10-31 Rinat Neuroscience Corp Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos.
CA2608018C (en) 2005-05-12 2010-07-13 Pfizer Inc. Anhydrous crystalline forms of n-[1-(2-ethoxyethyl)-5-(n-ethyl-n-methylamino)-7-(4-methylpyridin-2-yl-amino)-1h-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide
CA2608672A1 (en) 2005-05-24 2006-11-30 Pharmacia & Upjohn Company Llc Pyridine [3,4-b] pyrazinones as pde-5 inhibitors
WO2006126083A1 (en) 2005-05-24 2006-11-30 Pharmacia & Upjohn Company Llc Pyridine [3 , 4-b] pyrazinone compounds as pde-5 inhibitors
WO2006126081A2 (en) 2005-05-24 2006-11-30 Pharmacia & Upjohn Company Llc Pyridino [2 , 3-b] pyrazinones as pde-5 inhibitors
DE602006018301D1 (de) 2005-06-22 2010-12-30 Pfizer Prod Inc Histamin-3-rezeptorantagonisten
DE102005040694A1 (de) 2005-08-27 2007-03-01 Schaeffler Kg Ventiltrieb mit mechanischer Ventilspieleinstellung und Verfahren zu dessen Montage
CA2628074C (en) 2005-10-25 2014-01-14 Shionogi & Co., Ltd. Aminodihydrothiazine derivative
US8158673B2 (en) 2005-10-27 2012-04-17 Pfizer Inc. Histamine-3 receptor antagonists
CA2624625A1 (en) 2005-11-04 2007-05-10 Pfizer Limited Tetrahydronaphthyridine derivative
WO2007063385A2 (en) 2005-12-01 2007-06-07 Pfizer Products Inc. Spirocyclic amine histamine-3 receptor antagonists
WO2007069053A1 (en) 2005-12-14 2007-06-21 Pfizer Products Inc. Benzimidazole antagonists of the h-3 receptor
WO2007088450A2 (en) 2006-02-01 2007-08-09 Pfizer Products Inc. Chromane antagonist of the h-3 receptor
WO2007088462A1 (en) 2006-02-01 2007-08-09 Pfizer Products Inc. Spirochromane antagonists of the h-3 receptor
WO2007099423A1 (en) 2006-03-02 2007-09-07 Pfizer Products Inc. 1-pyrrolidine indane derivatives as histamine-3 receptor antagonists
CA2643055A1 (en) 2006-03-13 2007-09-20 Pfizer Products Inc. Tetralines antagonists of the h-3 receptor
EP2010520B1 (en) 2006-04-20 2012-09-12 Pfizer Products Inc. Heterobicyclic amides for the prevention and treatment of glucokinase-mediated diseases
AU2007242555B2 (en) 2006-04-21 2010-12-16 Pfizer Products Inc. Pyridine[3,4-b]pyrazinones
WO2007138431A2 (en) 2006-05-30 2007-12-06 Pfizer Products Inc. Azabicyclic ether histamine-3 antagonists
BRPI0721053A2 (pt) 2006-11-29 2014-07-29 Pfizer Prod Inc INIBIDORES DE ESPIROCETONA ACETIL-CoA CARBOXILASE
JP4585610B2 (ja) 2007-01-22 2010-11-24 ファイザー・プロダクツ・インク 治療用化合物のトシル酸塩およびその医薬組成物
US20090036425A1 (en) 2007-08-02 2009-02-05 Pfizer Inc Substituted bicyclolactam compounds
US9321730B2 (en) 2007-08-21 2016-04-26 The Hong Kong Polytechnic University Method of making and administering quinoline derivatives as anti-cancer agents
PL2233474T3 (pl) 2008-01-18 2015-12-31 Eisai R&D Man Co Ltd Skondensowana pochodna aminodihydrotiazyny
JP5435592B2 (ja) 2008-05-28 2014-03-05 ファイザー・インク ピラゾロスピロケトンアセチルＣｏＡカルボキシラーゼ阻害剤
WO2009144555A1 (en) 2008-05-28 2009-12-03 Pfizer Inc. Pyrazolospiroketone acetyl-coa carboxylase inhibitors
JP2011529483A (ja) 2008-07-29 2011-12-08 ファイザー・インク フッ素化ヘテロアリール
AU2009286380B2 (en) 2008-08-28 2011-09-15 Pfizer Inc. Dioxa-bicyclo[3.2.1.]octane-2,3,4-triol derivatives
JP5666304B2 (ja) 2008-09-30 2015-02-12 エーザイ・アール・アンド・ディー・マネジメント株式会社 新規な縮合アミノジヒドロチアジン誘導体
TW201038580A (en) 2009-02-02 2010-11-01 Pfizer 4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl derivatives
EP2604604A1 (en) 2009-03-11 2013-06-19 Pfizer Inc Benzofuranyl derivatives used as glucokinase inhibitors
CA2754685A1 (en) 2009-03-11 2010-09-16 Pfizer Inc. Substituted indazole amides
WO2010106457A2 (en) 2009-03-20 2010-09-23 Pfizer Inc. 3-oxa-7-azabicyclo[3.3.1]nonanes
US20120052130A1 (en) 2009-05-08 2012-03-01 Pfizer Inc. Gpr 119 modulators
CA2759843A1 (en) 2009-05-08 2010-11-10 Pfizer Inc. Gpr 119 modulators
US20100285145A1 (en) 2009-05-08 2010-11-11 Pfizer Inc Gpr 119 modulators
NZ596467A (en) 2009-06-05 2014-01-31 Pfizer L- ( piperidin-4-yl) -pyrazole derivatives as gpr 119 modulators
AR077277A1 (es) 2009-07-09 2011-08-17 Lilly Co Eli Compuestos de biciclo (1,3)tiazin-2-amina formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de la enfermedad de alzheimer
WO2011005611A1 (en) 2009-07-09 2011-01-13 Merck Sharp & Dohme Corp. Neuromedin u receptor agonists and uses thereof
GB0912778D0 (en) 2009-07-22 2009-08-26 Eisai London Res Lab Ltd Fused aminodihydro-oxazine derivatives
US8188079B2 (en) 2009-08-19 2012-05-29 Hoffman-La Roche Inc. 3-amino-5-phenyl-5,6-dihydro-2H-[1,4]oxazines
UA108363C2 (uk) 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
JPWO2011071109A1 (ja) 2009-12-11 2013-04-22 塩野義製薬株式会社 アミノ基を有する縮合ヘテロ環化合物
GB201101139D0 (en) 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
BR112013026341A2 (pt) 2011-04-13 2019-09-24 Merck Sharp & Dohe Corp composto, composição farmacêutica, e, método para tratar, prevenir e/ou atrasar o início de uma doença ou patologia
AR086539A1 (es) * 2011-05-24 2014-01-08 Bristol Myers Squibb Co COMPUESTOS PARA LA REDUCCION DE LA PRODUCCION DE b-AMILOIDE
JP6043355B2 (ja) 2011-08-31 2016-12-14 ファイザー・インク ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物
WO2013164730A1 (en) 2012-05-04 2013-11-07 Pfizer Inc. Heterocyclic substituted hexahydropyrano [3,4-d] [1,3] thiazin- 2 -amine compounds as inhibitors of app, bace1 and bace 2.
EP2897964A1 (en) 2012-09-20 2015-07-29 Pfizer Inc. Alkyl-substituted hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds
EP2931731A1 (en) 2012-12-11 2015-10-21 Pfizer Inc. Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds as inhibitors of bace1
US9403846B2 (en) 2012-12-19 2016-08-02 Pfizer Inc. Carbocyclic- and heterocyclic-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
EP2956458B1 (en) 2013-02-13 2017-08-09 Pfizer Inc Heteroaryl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
US9233981B1 (en) 2013-02-15 2016-01-12 Pfizer Inc. Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
EP3119347B1 (en) 2014-03-21 2023-06-07 Align Technology, Inc. Segmented orthodontic appliance with elastics
CN106459088A (zh) 2014-04-10 2017-02-22 辉瑞公司 2‑氨基‑6‑甲基‑4，4a，5，6‑四氢吡喃并[3，4‑d][1，3]噻嗪‑8a(8H)‑基‑1，3‑噻唑‑4‑基酰胺
JP2018531923A (ja) 2015-09-24 2018-11-01 ファイザー・インク Ｎ−［２−（２−アミノ−６，６−二置換−４，４ａ，５，６−テトラヒドロピラノ［３，４−ｄ］［１，３］チアジン−８ａ（８Ｈ）−イル）−１，３−チアゾール−４−イル］アミド
WO2017051303A1 (en) 2015-09-24 2017-03-30 Pfizer Inc. Tetrahydropyrano[3,4-d][1,3]oxazin derivatives and their use as bace inhibitors
JP2018534251A (ja) 2015-09-24 2018-11-22 ファイザー・インク Ｂａｃｅ阻害剤として有用なｎ−［２−（３−アミノ−２，５−ジメチル−１，１−ジオキシド−５，６−ジヒドロ−２ｈ−１，２，４−チアジアジン−５−イル）−１，３−チアゾール−４−イル］アミド

Also Published As

Publication number Publication date
CL2016002510A1 (es) 2017-01-06
CR20160455A (es) 2016-12-16
US20160152637A1 (en) 2016-06-02
US20150291621A1 (en) 2015-10-15
MD20160105A2 (ro) 2017-03-31
MA39866A (fr) 2017-02-15
MX2016013329A (es) 2017-01-26
US9315520B2 (en) 2016-04-19
EA030085B1 (ru) 2018-06-29
AU2015245260A1 (en) 2016-10-06
CU20160151A7 (es) 2017-02-02
CA2944971A1 (en) 2015-10-15
JP6111002B1 (ja) 2017-04-05
US20170008911A1 (en) 2017-01-12
ZA201606517B (en) 2017-11-29
EA201600636A1 (ru) 2017-02-28
IL248277A0 (en) 2016-11-30
US9605007B2 (en) 2017-03-28
DOP2016000276A (es) 2017-02-28
AP2016009493A0 (en) 2016-10-31
US20170151252A1 (en) 2017-06-01
TWI551605B (zh) 2016-10-01
KR20180078347A (ko) 2018-07-09
EP3129388A1 (en) 2017-02-15
US9744173B2 (en) 2017-08-29
US10028962B2 (en) 2018-07-24
CA2944971C (en) 2019-05-07
US20170304312A1 (en) 2017-10-26
SV2016005294A (es) 2017-07-28
KR101875811B1 (ko) 2018-07-06
SG11201607896YA (en) 2016-10-28
PE20170327A1 (es) 2017-04-21
JP2017511809A (ja) 2017-04-27
CN106459088A (zh) 2017-02-22
PH12016501977A1 (en) 2017-01-09
TW201542568A (zh) 2015-11-16
UY36073A (es) 2015-11-30
WO2015155626A1 (en) 2015-10-15
US9428523B2 (en) 2016-08-30
KR20160140944A (ko) 2016-12-07

Similar Documents

Publication Publication Date Title
ECSP16079730A (es) 2-AMINO-6-METIL-4,4a,5,6-TETRAHIDROPIRANO[3,4-d][1,3]TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILAMIDAS
MX2018005890A (es) Composiciones para tratar atrofia muscular espinal.
CR20140464A (es) Compuestos de heterociclilo
GT201400301A (es) 7h-pirrolo [2,3-d] pirimidinas-4- ( aminho-substituidas) novedosas como inhibidores de lrrk2
MX2016014547A (es) Compuestos para tratar atrofia muscular espinal.
CY1118379T1 (el) Αναστολεις ιου ηπατιτιδας c
ECSP16076566A (es) Compuestos de heteroarilo o arilo biciclicos fusionados y su aplicación a inhibidores de irak4
MX2018006637A (es) Antagonistas policiclicos del receptor 7/8 tipo toll (tlr7/8) y uso de los mismos en el tratamiento de trastornos inmunitarios.
UA116648C2 (uk) Фумарати як проліки та їх застосування при лікуванні різних захворювань
MX375970B (es) Compuestos de triazolopirimidina y usos de los mismos.
UY35320A (es) ?COMPUESTOS DE HEXAHIDROPIRANO[3,4-d][1,3]TIAZIN-2-AMINA SUSTITUIDA CON HETEROARILO?.
MD4666B1 (ro) Inhibitori ai Syk
EA201591195A1 (ru) Новые хинолоновые производные
EA201492204A1 (ru) Нуклеозиды на основе урацила и спирооксетана
CR20140399A (es) Pirrolidina-2-carboxamidas sustituidas
UY33883A (es) Novedosos derivados heterocíclicos
IN2015DN01119A (es)
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
UY35182A (es) ?COMPUESTOS DE HEXAHIDROPIRANO[ 3,4-d][1,3]TIAZIN-2-AMINA? .
DOP2017000034A (es) Compuestos de imidazopiridazina
UY35551A (es) Derivados heteroarilos como inhibidores de aldosterona sintasa
EA201600434A1 (ru) Применение производных бензимидазолпролина
CO2017000443A2 (es) Derivados de 3h, 4h, 6h, 7h-piran[3,4-d]imidazol-4-ona activos como inhibidores de la aldosterona sintasa
EA201600619A1 (ru) Хромен и 1,1а, 2,7в-тетрагидроциклопропа[с]хромен пиридопиразиндионы в качестве модулятора гамма-секретазы
CR20160600A (es) Quinolizione derivados como inhibidores pi3k